The Entirely Subcutaneous Defibrillator (S-Icd): State of the Art and Selection of the Ideal Candidate

Author(s): Elia De Maria , Alina Olaru , Stefano Cappelli .

Journal Name: Current Cardiology Reviews

Volume 11 , Issue 2 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

The traditional transvenous defibrillator has been one of the greatest advancement in Cardiology in the last 30 years and has demonstrated to reduce arrhythmic and total mortality in selected patients. However the traditional defibrillator can have a high price to pay in terms of complications, the “weakest link” being the transvenous/endocardial leads. The entirely subcutaneous defibrillator (S-ICD) has recently entered into the clinical scenario and represents a valid alternative to the transvenous device. S-ICD can provide substantial advantages, especially among some subgroups of patients (i.e. after device infection, in young patients and arrhythmogenic syndromes). However, given its characteristics, it is fundamental to choose patients that can benefit the most. In this review we will describe advantages and limitations of the SICD and point-out how to select the “ideal candidate” for the implantation.

Keywords: Subcutaneous defibrillator, sudden cardiac death, ventricular arrhythmias.

[1]
Hohnloser SH, Israel CW. Current evidence base for use of the implantable cardioverter-defibrillator. Circulation 2013; 128(2): 172-83.
[2]
John RM, Tedrow UB, Koplan BA, et al. Ventricular arrhythmias and sudden cardiac death. Lancet 2012; 380(9852): 1520-9.
[3]
Katritsis DG, Josephson ME. Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics? Europace 2012; 14(6): 787-94.
[4]
Gasparini M, Nisam S. Implantable cardioverter defibrillator harm? Europace 2012; 14(8): 1087-93.
[5]
Atwater BD, Daubert JP. Implantable cardioverter defibrillators: risks accompany the life-saving benefits. Heart 2012; 98(10): 764-72.
[6]
Maisel WH. Transvenous implantable cardioverter-defibrillator leads: the weakest link. Circulation 2007; 115(19): 2461-3.
[7]
Maisel WH, Kramer DB. Implantable cardioverter-defibrillator lead performance. Circulation 2008; 117(21): 2721-3.
[8]
Kalahasty G, Ellenbogen KA. Management of the patient with implantable cardioverter-defibrillator lead failure. Circulation 2011; 123(12): 1352-4.
[9]
De Maria E, Bonetti L, Patrizi G, et al. Implantation of a completely subcutaneous ICD system: case report of a patient with Brugada syndrome and state of the art. J Interv Card Electrophysiol 2012; 34(1): 105-13.
[10]
Grace A. The subcutaneous implantable cardioverter-defibrillator. Curr Opin Cardiol 2014; 29(1): 10-9.
[11]
Akerström F, Arias MA, Pachón M, Puchol A, Jiménez-López J. Subcutaneous implantable defibrillator: State-of-the art 2013. World J Cardiol 2013; 5(9): 347-54.
[12]
Gold MR, Theuns DA, Knight BP, et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol 2012; 23(4): 359-66.
[13]
Rowley CP, Gold MR. Subcutaneous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2012; 5(3): 587-93.
[14]
Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363(1): 36-44.
[15]
Aydin A, Hartel F, Schlüter M, et al. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience. Circ Arrhythm Electrophysiol 2012; 5(5): 913-9.
[16]
Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm 2013; 10(1): 29-36.
[17]
Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol 2012; 60(19): 1933-9.
[18]
Jarman JW, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. Europace 2013; 15(8): 1158-65.
[19]
Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 2013; 128(9): 944-53.
[20]
Pedersen SS, Lambiase P, Boersma LV, et al. Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD: design and rationale of the EFFORTLESS S-ICD Registry. Pacing Clin Electrophysiol 2012; 35(5): 574-9.
[21]
Lambiase PD, Barr C, Theuns DA, et al. on behalf of the EFFORTLESS Investigators Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 2014; 35(25): 1657-65.
[22]
Poole JE, Gold MR. Who should receive the subcutaneous implanted defibrillator?: the subcutaneous implantable cardioverter defibrillator (icd) should be considered in all icd patients who do not require pacing. Circ Arrhythm Electrophysiol 2013; 6(6): 1236-45.
[23]
Killingsworth CR, Melnick SB, Litovsky SH, Ideker RE, Walcott GP. Evaluation of acute cardiac and chest wall damage after shocks with a subcutaneous implantable cardioverter defibrillator in Swine. Pacing Clin Electrophysiol 2013; 36(10): 1265-72.
[24]
Olde Nordkamp LR, Warnaars JL, Kooiman KM, et al. Which Patients Are Not Suitable for a Subcutaneous ICD: Incidence and Predictors of Failed QRS-T-Wave Morphology Screening. J Cardiovasc Electrophysiol 2014; 25(5): 494-9.
[25]
Kooiman KM, Knops RE, Olde Nordkamp L, Wilde AA, de Groot JR. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management. Heart Rhythm 2014; 11(3): 426-34.
[26]
Acha MR, Milan D. Who should receive the subcutaneous implanted defibrillator?: timing is not right to replace the transvenous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2013; 6(6): 1246-51.
[27]
Korkeila P, Nyman K, Ylitalo A, et al. Venous obstruction after pacemaker implantation. Pacing Clin Electrophysiol 2007; 30(2): 199-206.
[28]
De Maria E, Cappelli S, Cappato R. Shock efficacy of the entirely subcutaneous defibrillator for termination of spontaneous ventricular fibrillation in Brugada syndrome. Heart Rhythm 2013; 10(12): 1807-9.
[29]
Bloch Thomsen PE, Jons C, Raatikainen MJ, et al. Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) Study Group Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation 2010; 122(13): 1258-64.
[30]
de Bie MK, Thijssen J, van Rees JB, et al. Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice. Heart 2013; 99(14): 1018-23.
[31]
Olde Nordkamp LR, Knops RE, Bardy GH, et al. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J 2012; 163(5): 753-60.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 2
Year: 2015
Page: [180 - 186]
Pages: 7
DOI: 10.2174/1573403X10666140827094126
Price: $58

Article Metrics

PDF: 25
HTML: 2
EPUB: 1
PRC: 1